- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-IFNA2/ IFN-alphaA/ IFNAB functional antibody
Anti-IFNA2/ IFN-alphaA/ IFNAB functional antibody for cell culture, ELISA & in-vivo assay
Go to IFNA2/IFNA2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T63934-Ab-1/ GM-Tg-hg-T63934-Ab-2 | Anti-Human IFNA2 monoclonal antibody | Human |
| GM-Tg-rg-T63934-Ab-1/ GM-Tg-rg-T63934-Ab-2 | Anti-Rat IFNA2 monoclonal antibody | Rat |
| GM-Tg-mg-T63934-Ab-1/ GM-Tg-mg-T63934-Ab-2 | Anti-Mouse IFNA2 monoclonal antibody | Mouse |
| GM-Tg-cynog-T63934-Ab-1/ GM-Tg-cynog-T63934-Ab-2 | Anti-Cynomolgus/ Rhesus macaque IFNA2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T63934-Ab-1/ GM-Tg-felg-T63934-Ab-2 | Anti-Feline IFNA2 monoclonal antibody | Feline |
| GM-Tg-cang-T63934-Ab-1/ GM-Tg-cang-T63934-Ab-2 | Anti-Canine IFNA2 monoclonal antibody | Canine |
| GM-Tg-bovg-T63934-Ab-1/ GM-Tg-bovg-T63934-Ab-2 | Anti-Bovine IFNA2 monoclonal antibody | Bovine |
| GM-Tg-equg-T63934-Ab-1/ GM-Tg-equg-T63934-Ab-2 | Anti-Equine IFNA2 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T63934-Ab-1/ GM-Tg-hg-T63934-Ab-2; GM-Tg-rg-T63934-Ab-1/ GM-Tg-rg-T63934-Ab-2; GM-Tg-mg-T63934-Ab-1/ GM-Tg-mg-T63934-Ab-2; GM-Tg-cynog-T63934-Ab-1/ GM-Tg-cynog-T63934-Ab-2; GM-Tg-felg-T63934-Ab-1/ GM-Tg-felg-T63934-Ab-2; GM-Tg-cang-T63934-Ab-1/ GM-Tg-cang-T63934-Ab-2; GM-Tg-bovg-T63934-Ab-1/ GM-Tg-bovg-T63934-Ab-2; GM-Tg-equg-T63934-Ab-1/ GM-Tg-equg-T63934-Ab-2 |
| Products Name | Anti-IFNA2 monoclonal antibody |
| Format | mab |
| Target Name | IFNA2 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-IFNA2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-T63934-Ag-1 | Recombinant multi-species IFNA2/ IFN-alphaA/ IFNAB protein |
| Cytokine | GM-Tg-g-T63934-Ag-1 | IFNA2 interferon, alpha 2 (IFNA2) protein |
| ORF Viral Vector | pGMLP004490 | human IFNA2 Lentivirus plasmid |
| ORF Viral Vector | vGMLP004490 | human IFNA2 Lentivirus particle |
| ORF Viral Vector | pGMLPm004502 | mouse Ifna2 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004502 | mouse Ifna2 Lentivirus particle |
Target information
| Target ID | GM-T63934 |
| Target Name | IFNA2 |
| Gene ID | 3440 |
| Gene Symbol and Synonyms | IFN-alpha-2,IFN-alphaA,IFNA,IFNA2,IFNA2B,leIF A |
| Uniprot Accession | P01563 |
| Uniprot Entry Name | IFNA2_HUMAN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, Cytokine Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000188379 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: IFNA2, gene name: IFNA2, also named as IFN-alphaA, IFNAB, INFA2, IFNA2. This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
